Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non- controlling Interest
Beginning balance (in shares) at Sep. 30, 2023		107,312,000
Beginning balance at Sep. 30, 2023	$ 287,162	$ 200	$ 1,300,395	$ (3,222)	$ (1,026,030)	$ 15,819
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	19,694		19,694
Exercise of stock options (in shares)		34,000
Exercise of stock options	267		267
Common stock - restricted stock units vesting (in shares)		154,000
Foreign currency translation adjustments	58			58
Unrealized gains (losses) on available-for-sale securities	1,909			1,909
Net income (loss)	(135,376)				(132,864)	(2,512)
Ending balance (in shares) at Dec. 31, 2023		107,500,000
Ending balance at Dec. 31, 2023	173,714	$ 200	1,320,356	(1,255)	(1,158,894)	13,307
Beginning balance (in shares) at Sep. 30, 2023		107,312,000
Beginning balance at Sep. 30, 2023	287,162	$ 200	1,300,395	(3,222)	(1,026,030)	15,819
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation adjustments	2
Unrealized gains (losses) on available-for-sale securities	2,125
Net income (loss)	(262,372)
Ending balance (in shares) at Mar. 31, 2024		124,133,000
Ending balance at Mar. 31, 2024	495,405	$ 217	1,768,866	(1,095)	(1,284,194)	11,611
Beginning balance (in shares) at Dec. 31, 2023		107,500,000
Beginning balance at Dec. 31, 2023	173,714	$ 200	1,320,356	(1,255)	(1,158,894)	13,307
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	17,750		17,750
Exercise of stock options (in shares)		120,000
Exercise of stock options	1,512		1,512
Common stock - restricted stock units vesting (in shares)		723,000
Common stock - restricted stock units vesting	0	$ 1	(1)
Common stock issued, net of offering costs (in shares)		15,790,000
Common stock issued, net of offering costs	429,265	$ 16	429,249
Foreign currency translation adjustments	(56)			(56)
Unrealized gains (losses) on available-for-sale securities	216			216
Net income (loss)	(126,996)				(125,300)	(1,696)
Ending balance (in shares) at Mar. 31, 2024		124,133,000
Ending balance at Mar. 31, 2024	495,405	$ 217	1,768,866	(1,095)	(1,284,194)	11,611
Beginning balance (in shares) at Sep. 30, 2024		124,376,000
Beginning balance at Sep. 30, 2024	191,063	$ 217	1,806,000	4,750	(1,625,523)	5,619
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	15,209		15,209
Exercise of stock options (in shares)		70,000
Exercise of stock options	634		634
Common stock - restricted stock units vesting (in shares)		209,000
Issuance of pre-funded warrants	25,000		25,000
Foreign currency translation adjustments	(106)			(106)
Unrealized gains (losses) on available-for-sale securities	(507)			(507)
Net income (loss)	(175,218)				(173,085)	(2,133)
Ending balance (in shares) at Dec. 31, 2024		124,655,000
Ending balance at Dec. 31, 2024	56,075	$ 217	1,846,843	4,137	(1,798,608)	3,486
Beginning balance (in shares) at Sep. 30, 2024		124,376,000
Beginning balance at Sep. 30, 2024	$ 191,063	$ 217	1,806,000	4,750	(1,625,523)	5,619
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	422,333
Foreign currency translation adjustments	$ (506)
Unrealized gains (losses) on available-for-sale securities	146
Net income (loss)	192,645
Ending balance (in shares) at Mar. 31, 2025		138,062,000
Ending balance at Mar. 31, 2025	684,225	$ 230	2,106,864	4,390	(1,428,163)	904
Beginning balance (in shares) at Dec. 31, 2024		124,655,000
Beginning balance at Dec. 31, 2024	56,075	$ 217	1,846,843	4,137	(1,798,608)	3,486
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	16,027		16,027
Exercise of stock options (in shares)		353,000
Exercise of stock options	2,619		2,619
Common stock - restricted stock units vesting (in shares)		1,128,000
Common stock - restricted stock units vesting	1	$ 1
Common stock issued, net of offering costs (in shares)		11,926,000
Common stock issued, net of offering costs	241,387	$ 12	241,375
Foreign currency translation adjustments	(400)			(400)
Unrealized gains (losses) on available-for-sale securities	653			653
Net income (loss)	367,863				370,445	(2,582)
Ending balance (in shares) at Mar. 31, 2025		138,062,000
Ending balance at Mar. 31, 2025	$ 684,225	$ 230	$ 2,106,864	$ 4,390	$ (1,428,163)	$ 904